Glycopyrrolate, a synthetic quarternary ammonium compound, has a similar pharmacologic property to that of scopolamine, a belladonna alkaloid. Since glycopyrrolate, a quarternary ammonium compound, dose not readily cross the blood brain barrier, it has less central effect than that of scopoiamine a tertiary-amine compound. The authors administered a small dose of scopolamine and glycopyrrolate to human volunteers, and examined the effect on the heart rate ofr both drugs. The results were as follows: 1) A small dose of scopolamine(0.1mg) showed significnat decrease in the heart rate. 2) A small dose of gylcopyrrolate(0.1mg) indeced little change in the heart rate. 3) A small dose of gylcopyrrolate(0.1mg), 10minutes after glycopyrrolate(0.1mg), showed marked increase in the heart rate. 4) A small dose of scopolamine(0.1mg), given 10 minutes after glycopyrrolate (0.1mg), showed tendency for decrease in heart kate. 5) A small dose of gylcopyrrolate(0.1mg), 10 minutes afterscopolamine(0.1mg), showed significant increases in the heart rate. 6) Scopolamine induced bradycardia was suppressed by an additional dose of glycopyrrolate and a preceding dose of glycopyrrolate.
Humans

No abstract available.
Humans

PURPOSE: To assess the usefulness and reliability of the IOL power calculation computer program ('POWER!'). METHODS: Calculation times and projected postoperative refractive values of 100 patients with 'POWER!' program were compared with those of the program mounted on the Humphrey R A/B scan system (model 820) by SRK-II and SRK/T formula. RESULTS: There was no significant difference between the projected postoperative refractive values of 'POWER!' program and Humphrey R A/B scan system (paired-t test, p>0.05). Calculation time of 'POWER!' was shorter than that of the program mounted on the Humphrey R A/B scan system incalculating more than 3 sets of IOL (paired-t test, P<0.05) and there was no internal calculation error (ztest, p>0.05). CONCLUSIONS: 'POWER!' is a useful and reliable program for IOL power calculation using SRK-II and SRK/T formula.
Humans

Noninferiority trials test whether a new experimental treatment is not unacceptably less efficacious than an active control treatment already in use. With continuous improvements in health technologies, standard care, and clinical outcomes, the incremental benefits of newly developed treatments may be only marginal over existing treatments. Sometimes assigning patients to a placebo is unethical. In such circumstances, there has been increasing emphasis on the use of noninferiority trial designs. Noninferiority trials are more complex to design, conduct, and interpret than typical superiority trials. This paper reviews the concept of noninferiority trials and discusses some important issues related to them.
Humans

No abstract available.
Humans

No abstract available.
Humans

No abstract available.
Humans

No abstract available.
Humans

No abstract available.
Humans

Squamous papilloma is a commom benign lesion of the oral mucosa, but rarely encountered in dermatologic practice. Usually, oral squamous papilloma is a solitary peduculated lesion with verrucous surface, and known to be associated with human papilloma virus (HPV). We experienced a histologically confirmed case of oral squamous papilloma which occured in a 54-year-old man.
Humans